Bosh sahifaGLAXO • NSE
add
GlaxoSmithKline Pharmaceuticals Ltd
Yopilish kursi
2 473,60 ₹
Kunlik diapazon
2 442,50 ₹ - 2 476,00 ₹
Yillik diapazon
1 921,00 ₹ - 3 515,70 ₹
Bozor kapitalizatsiyasi
415,61 mlrd INR
Oʻrtacha hajm
92,20 ming
Narx/foyda
43,56
Dividend daromadliligi
1,71%
Asosiy maydon
NSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (INR) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 9,80 mlrd | -3,05% |
Joriy xarajat | 3,06 mlrd | -4,77% |
Sof foyda | 2,57 mlrd | 1,98% |
Sof foyda marjasi | 26,28 | 5,20% |
Har bir ulushga tushum | — | — |
EBITDA | 3,35 mlrd | 4,13% |
Amaldagi soliq stavkasi | 27,26% | — |
Balans
Jami aktivlari
Jami passivlari
| (INR) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 20,61 mlrd | -2,36% |
Jami aktivlari | 36,65 mlrd | -2,16% |
Jami passivlari | 19,57 mlrd | -5,59% |
Umumiy kapital | 17,08 mlrd | — |
Tarqatilgan aksiyalar | 169,40 mln | — |
Narxi/balansdagi bahosi | 24,54 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | 42,96% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (INR) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,57 mlrd | 1,98% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Tashkil etilgan
13-noy, 1924
Xodimlar soni
3 113
